MedPath

Ganirelix Acetate

Ganirelix Acetate Injection

Approved
Approval ID

c23ca7b2-7350-4f07-8adf-046bffb47842

Product Type

HUMAN PRESCRIPTION DRUG LABEL

Effective Date

Mar 14, 2023

Manufacturers
FDA

Fresenius Kabi USA, LLC

DUNS: 013547657

Products 1

Detailed information about drug products covered under this FDA approval, including NDC codes, dosage forms, ingredients, and administration routes.

Ganirelix Acetate

Product Details

FDA regulatory identification and product classification information

FDA Identifiers
NDC Product Code65219-028
Application NumberANDA215658
Product Classification
M
Marketing Category
C73584
G
Generic Name
Ganirelix Acetate
Product Specifications
Route of AdministrationSUBCUTANEOUS
Effective DateFebruary 1, 2023
FDA Product Classification

INGREDIENTS (5)

mannitolInactive
Quantity: 23.5 mg in 0.5 mL
Code: 3OWL53L36A
Classification: IACT
Ganirelix AcetateActive
Quantity: 250 ug in 0.5 mL
Code: 56U7906FQW
Classification: ACTIB
waterInactive
Code: 059QF0KO0R
Classification: IACT
acetic acidInactive
Quantity: 0.1 mg in 0.5 mL
Code: Q40Q9N063P
Classification: IACT
sodium hydroxideInactive
Code: 55X04QC32I
Classification: IACT

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.

Ganirelix Acetate - FDA Drug Approval Details